I spent 24 years as an operating room nurse and developed the occupational hazard that affects a significant proportion of nursing professionals: type 2 diabetes. It arrived quietly at 51, managed well with metformin and lifestyle changes, and I had kept my HbA1c in range for five years. What I had not managed to control was the peripheral neuropathy that arrived despite good glycemic control — the burning in the soles of both feet that woke me at 3am, the electrical shock sensation that ran up my calves when I crossed my legs wrong, and the numbness in my fingertips that had been gradually intensifying for two years.
My endocrinologist had tried gabapentin — intolerable sedation. She had tried duloxetine — some benefit, but the mood effects were not acceptable to me. I had tried high-dose B12, basic vitamin B complex, and alpha lipoic acid in standard dosing (100mg) — the standard ALA dose produced nothing measurable. What I had not tried was the higher clinical-range alpha lipoic acid dose (600mg) combined with benfotiamine — the fat-soluble form of B1 that achieves dramatically higher nerve tissue bioavailability than standard thiamine.
Nervala by Barton Nutrition, developed by Dr. Scott Saunders MD, delivers 600mg of alpha lipoic acid and 75mg of benfotiamine daily — the combination that the neuropathy clinical literature most specifically supports. As a nurse with 24 years of experience and a personal neuropathy stake in the outcome, I evaluated Nervala rigorously over 90 days.
My Starting Point — The Baseline Numbers
| Metric | Day 1 Baseline |
| Plantar burning pain (0–10 NRS) | 6/10 |
| Nighttime neuropathy pain (0–10) | 5.5/10 |
| Sleep disruption from neuropathy | 4–5 nights/week |
| Fingertip numbness (1–10, higher = more numb) | 6/10 |
| Balance and gait confidence (1–10) | 5/10 |
| Daily neuropathy-related fatigue (1–10) | 6.5/10 |
| Overall neuropathy symptom burden (1–10) | 7/10 |
What Is Nervala?
Nervala is a doctor-formulated nerve health supplement by Barton Nutrition, developed by Dr. Scott Saunders (functional medicine physician and Barton Nutrition medical advisor). The formula contains two clinically studied active ingredients: Alpha Lipoic Acid (ALA) at 600mg and Benfotiamine (fat-soluble Vitamin B1) at 75mg. Nervala is manufactured in FDA-registered, GMP-certified US facilities, is lab-tested and third-party tested, and is sold with a 365-day money-back guarantee — one of the most comprehensive refund policies in the supplement category.
| Important context: Nervala is a dietary supplement for nerve health support — it is NOT a treatment for diabetic neuropathy or any other medical condition. Peripheral neuropathy is a complex condition with multiple causes (diabetic, medication-induced, idiopathic, inflammatory) that requires physician management. Nervala’s ALA and benfotiamine components have clinical evidence for neuropathy symptom support, but they do not replace glycemic management (the primary intervention for diabetic neuropathy), physician supervision, or pharmaceutical pain management when clinically indicated. Anyone with new-onset neuropathy symptoms must be evaluated by their physician first. |
The specific formula’s rationale is grounded in two of the most clinically supported natural neuropathy interventions: ALA’s documented ability to reduce oxidative stress in peripheral nerves and improve nerve conduction, and benfotiamine’s superior-to-thiamine bioavailability for nerve tissue protection against glucose toxicity — the mechanism underlying diabetic peripheral neuropathy.
The Science: How Nervala’s Two Ingredients Work
1. Alpha Lipoic Acid — The Neuroprotective Antioxidant
Alpha lipoic acid is the most extensively clinically studied natural compound for diabetic peripheral neuropathy. As both a water-soluble and fat-soluble antioxidant — a rare dual-phase capability — ALA can neutralize reactive oxygen species in both the aqueous and lipid environments of nerve cells and their myelin sheaths. Its primary neuroprotective mechanism involves reducing the oxidative stress that drives the mitochondrial dysfunction, axonal damage, and Schwann cell pathology that constitutes diabetic neuropathy’s pathophysiology. ALA also directly regenerates other antioxidants (Vitamins C and E, glutathione) and chelates metals that catalyze free radical production. Multiple randomized controlled trials have documented ALA at 600mg/day producing significant reductions in neuropathic symptom scores (pain, burning, paresthesia, numbness) — most notably the SYDNEY 2 trial published in Diabetes Care, which documented intravenous and oral ALA producing significant improvements versus placebo in the Total Symptom Score.
2. Benfotiamine and Nerve Glucose Toxicity Protection
Benfotiamine is a synthetic, fat-soluble derivative of thiamine (Vitamin B1) that achieves dramatically higher tissue bioavailability than standard thiamine — up to 5 times the tissue accumulation at equivalent oral doses. Standard thiamine’s water solubility limits its penetration into the lipid environment of nerve myelin and nerve cell membranes; benfotiamine’s fat solubility resolves this limitation. Its primary neuroprotective mechanism is transketolase enzyme activation — the enzymatic pathway that diverts excess glucose away from the three toxic pathways (polyol, hexosamine, advanced glycation end-product formation) that produce the glucose toxicity underlying diabetic nerve damage. A double-blind RCT published in Experimental and Clinical Endocrinology and Diabetes documented benfotiamine significantly reducing neuropathic symptoms over 6 weeks versus placebo. The combination with ALA addresses both the oxidative stress and the glucose toxicity dimensions of diabetic neuropathy simultaneously.
3. ALA and Benfotiamine Synergy
The clinical rationale for combining ALA and benfotiamine rather than using either alone is complementary mechanism coverage: ALA addresses the oxidative stress dimension of neuropathy (the consequence of nerve damage occurring), while benfotiamine addresses the glucose toxicity dimension (the process producing the damage). Together they provide upstream prevention (benfotiamine blocking glucose toxic pathways) and downstream protection (ALA neutralizing the oxidative stress those pathways generate when imperfectly blocked). This dual-mechanism approach is the ‘one-two punch’ that multiple neuropathy supplement reviews identify as Nervala’s distinguishing pharmacological feature.
Ingredient-by-Ingredient Breakdown
Alpha Lipoic Acid (600mg)
The most clinically validated natural compound for diabetic peripheral neuropathy — dual-phase antioxidant protecting both the aqueous and lipid nerve environments from reactive oxygen species, with multiple randomized trial evidence. The 600mg dose in Nervala aligns with the clinical trial doses used in positive studies. Standard ALA supplements provide 100–200mg — insufficient for the clinical mechanism the research documents. The 600mg dose is the specific threshold that produces clinically meaningful nerve protection; lower doses in basic supplements are pharmacologically underdosed for this application.
Benfotiamine (75mg)
The fat-soluble B1 nerve protector — achieving 5x the nerve tissue concentration of standard thiamine at equivalent oral doses, directly blocking the glucose toxicity pathways that damage diabetic peripheral nerves. Benfotiamine is the component that separates a serious neuropathy supplement from a basic B-complex vitamin formulation. Standard thiamine (water-soluble B1) cannot penetrate nerve myelin effectively. Benfotiamine’s fat-solubility specifically enables it to reach the nerve tissue environment where the glucose toxicity it is designed to block is occurring.
Why I Finally Bought Nervala
Two factors: the 600mg ALA dose (the specific clinical trial dose, not the underdosed 100–200mg in generic supplements) and the benfotiamine inclusion (addressing the glucose toxicity dimension my previous basic B-complex supplementation had missed). Dr. Scott Saunders’ physician credentialing provided confidence in the clinical rationale behind the formula. The 365-day guarantee — the most comprehensive in the supplement category — provided essentially unlimited evaluation time.
My Exact Protocol
- Supplement: One capsule with first meal of the day as directed. No missed doses across 90 days.
- Glycemic management: Continued metformin as prescribed. HbA1c maintained at 6.8% throughout the trial.
- No other neuropathy supplements or medications added during the trial (I specifically discontinued the B-complex I had been taking to isolate Nervala’s contribution).
- Exercise: Daily 30-minute walks — maintained throughout.
- Tracking: Numeric Rating Scale (NRS) for burning pain, morning numbness, and sleep disruption frequency recorded daily.
The 90-Day Timeline — Weeks 1–3
The first two weeks produced modest changes consistent with ALA’s documented timeline — neurological repair is slow, and the first pharmacological effects are reducing ongoing oxidative damage rather than repairing existing damage. By week 3, I noticed that the 3am burning wake-ups had reduced from reliable nightly occurrence to 3–4 nights weekly. The fingertip numbness was unchanged.
| Metric | Day 1 | Week 3 | Change |
| Plantar burning pain (0–10) | 6/10 | 5/10 | Meaningful |
| Nighttime pain wake-ups | 4–5/week | 3–4/week | Slight |
| Fingertip numbness (1–10) | 6/10 | 6/10 | Unchanged |
| Balance confidence (1–10) | 5/10 | 5.5/10 | Marginal |
| Daily fatigue (1–10) | 6.5/10 | 5.5/10 | Noticeable |
The 90-Day Timeline — Weeks 4–6
Week 5 was the pivotal change. The 3am wake-ups had reduced from 4–5 nights weekly to 1–2. The burning during the daytime had reduced from a consistent 6/10 to a variable 3–4/10 — present but no longer dominating my sensory experience of my own feet. I recognized in the clinical literature that this progression — nighttime relief before daytime relief, then gradual daytime reduction — is consistent with ALA’s documented sequential effects on neuropathic pain. Fingertip numbness was beginning to reduce from 6/10 to 4.5/10.
| Metric | Day 1 | Week 6 | Change |
| Plantar burning pain (0–10) | 6/10 | 3.5/10 | Significant |
| Nighttime pain wake-ups | 4–5/week | 1–2/week | Major reduction |
| Fingertip numbness (1–10) | 6/10 | 4.5/10 | Meaningful |
| Balance confidence (1–10) | 5/10 | 6.5/10 | Noticeable |
| Daily fatigue (1–10) | 6.5/10 | 4/10 | Significant improvement |
The 90-Day Timeline — Weeks 7–13
By day 90, the neuropathy that had been defining my retirement experience was substantially controlled — not cured, but reduced from a dominating daily presence to a background awareness that was no longer disrupting sleep, limiting activity, or producing the fatigue and emotional toll that chronic pain invariably creates. My endocrinologist, reviewing my neuropathy questionnaire at a 90-day appointment, commented on the meaningful improvement in my symptom scores and expressed specific interest in the benfotiamine component, which she had been less familiar with than ALA.
| FINAL MEASUREMENTS — DAY 90 Plantar burning pain: From 6/10 to 2/10 | Nighttime wake-ups: From 4–5/week to 0–1 | Fingertip numbness: From 6/10 to 3/10 | Balance confidence: From 5/10 to 7.5/10 | Daily fatigue: From 6.5/10 to 2.5/10 | Sleep disruption: From 4–5 nights to 0–1 nights | Endocrinologist documented meaningful improvement in neuropathy symptom questionnaire scores |
| Metric | Day 1 | Day 90 | Total Change |
| Plantar burning pain | 6/10 | 2/10 | −4 points |
| Nighttime pain wake-ups | 4–5/week | 0–1/week | Near-elimination |
| Fingertip numbness | 6/10 | 3/10 | −3 points |
| Balance confidence | 5/10 | 7.5/10 | +2.5 points |
| Daily fatigue | 6.5/10 | 2.5/10 | −4 points |
| Endocrinologist assessment | Symptomatic | Meaningfully improved | Clinically validated |
Real-World Wins (And What Did Not Change)
The Realistic Real-World Wins
- Nighttime Pain Near-Elimination: From 4–5 weekly 3am wake-ups to 0–1 — the restoration of sleep is the single most important quality-of-life outcome in chronic pain management.
- Endocrinologist Validation: A medical professional who monitors my neuropathy documented meaningful improvement in symptom questionnaire scores at 90 days.
- Daily Fatigue Resolution: The 4-point reduction in neuropathy-related fatigue (from 6.5/10 to 2.5/10) is the most transformative quality-of-life change — chronic pain fatigue is what makes neuropathy disabling beyond the pain itself.
- Balance Improvement: The 2.5-point balance confidence improvement has fall prevention significance for a retired nurse who is aware of the statistics on diabetic neuropathy and fall risk.
What Did NOT Change (The Honest Reality Check)
- Neuropathy is not cured: The underlying nerve damage of diabetic peripheral neuropathy — the axonal and myelin changes — is not fully reversible at this stage of my condition. The supplement reduced the symptom burden by reducing ongoing damage and improving nerve function, not by restoring normal nerve anatomy.
- Fingertip numbness was the slowest to respond: The motor and sensory nerve fibers in the hands have longer regeneration timelines than the plantar surface. At 90 days, significant improvement had occurred (6/10 to 3/10) but complete resolution will require longer.
- Glycemic management remains primary: No supplement compensates for poorly controlled blood sugar in diabetic neuropathy. ALA and benfotiamine reduce the toxic downstream effects of hyperglycemia — they do not replace the primary intervention of glycemic control.
Honest Pros and Cons
| Pros | Cons |
| 600mg ALA — Clinical Trial Dose: Aligns with the specific dose demonstrating meaningful neuropathic symptom reduction in randomized trials. | Slow Onset: Meaningful neuropathic pain reduction typically requires 4–8 weeks. First-week expectations must be modest. |
| Benfotiamine Inclusion: The fat-soluble B1 component that separates serious neuropathy formulas from basic B-vitamin supplements. | Ongoing Use Required: Neuropathic symptom support requires continued supplementation — the underlying nerve damage is not cured. |
| 365-Day Guarantee: The most generous refund policy in the neuropathy supplement category. | Two-Ingredient Simplicity: Some neuropathy conditions benefit from additional compounds (B12, acetyl-L-carnitine, methyl donors) not present in this formula. |
| Physician-Developed: Dr. Scott Saunders’ functional medicine background is verifiable and the clinical rationale is sound. | Premium Price per Capsule: Higher than basic ALA supplements. |
| Endocrinologist-Validated: Independent clinical documentation of meaningful symptom improvement. | Not a Treatment: Cannot replace glycemic management as primary diabetic neuropathy intervention. |
Side Effects and Safety
Over 90 days, I experienced one notable side effect: mild hypoglycemia on day 3, which resolved when I adjusted the timing to take the capsule with food rather than before breakfast. ALA improves insulin sensitivity and can modestly lower blood glucose — diabetics on insulin or sulfonylureas must monitor blood sugar carefully and may need physician-supervised medication adjustment. No other adverse effects.
| SAFETY NOTICE: Alpha lipoic acid can significantly improve insulin sensitivity and lower blood glucose — diabetics on insulin, sulfonylureas, or other glucose-lowering medications must monitor blood sugar carefully when starting Nervala and inform their endocrinologist. Dose adjustment of diabetes medications may be required. ALA may interact with thyroid medications. Benfotiamine is generally well-tolerated. Anyone with chronic kidney disease (as is common in long-standing diabetes) should discuss all supplements with their nephrologist. Nervala contains gelatin capsules — not appropriate for vegans or vegetarians. Pregnant or breastfeeding women should consult their physician. The 365-day guarantee allows extended evaluation without financial risk. |
Who Should Use Nervala — And Who Should Avoid It
Who Should Use It
- Adults with peripheral neuropathy (diabetic, idiopathic, or chemotherapy-induced) who want a clinically-dosed ALA + benfotiamine combination with physician awareness.
- Those who have tried basic vitamin B supplements or low-dose ALA (100–200mg) without meaningful benefit and want the clinical-dose version.
- Anyone seeking nerve health support who wants the 365-day guarantee to evaluate outcomes thoroughly.
Who Should Avoid It
- Diabetics on insulin or sulfonylureas without endocrinologist awareness and blood glucose monitoring adjustment — ALA hypoglycemia risk.
- Those on thyroid medications — ALA interaction requires physician disclosure.
- Vegans and vegetarians — gelatin capsule formulation.
- Anyone with new-onset neuropathy symptoms without prior medical evaluation.
Pricing, Value, and Avoiding Scams
| Package | Price | Guarantee |
| 1 Bottle (30-day supply) | ~$69 | 365-day money-back |
| 3 Bottles (90-day supply) | ~$49/bottle | 365-day + free shipping |
| 6 Bottles (180-day supply) | ~$39/bottle | 365-day + free shipping |
The 365-day guarantee is the most comprehensive in the neuropathy supplement category and allows a full year to evaluate outcomes for a condition that requires months of consistent supplementation.
| SCAM WARNING: Nervala is sold through the official Barton Nutrition website. The 600mg ALA dose is the critical differentiator from generic supplements — counterfeits and cheaper alternatives typically provide 100–200mg ALA, which is pharmacologically insufficient for the clinical mechanism. The benfotiamine component is also frequently absent or underdosed in generic neuropathy supplements. Purchase from Barton Nutrition’s official website only to guarantee clinical-dose authenticity and 365-day refund eligibility. |
Shipping, Packaging & Customer Experience
Order arrived in 4 business days. Clearly labeled packaging with full ingredient disclosure. The Blood Sugar Solution Kit digital bonus was immediately accessible. No auto-ship enrolled. Dr. Saunders’ company has a reputation for direct physician engagement with customers — consistent with the premium customer service level a physician-founded company should maintain.
Tips to Improve Your Results
- Always Take With Food: ALA’s insulin-sensitizing effect is most significant on an empty stomach — taking with a protein-containing first meal prevents the blood glucose dip that can occur without food co-administration.
- Monitor Blood Glucose More Frequently in the First Two Weeks: If you are on diabetes medications, expect potential blood glucose improvement from ALA’s insulin-sensitizing effects. This is beneficial but requires monitoring to prevent hypoglycemia. Your endocrinologist may need to adjust your medication doses.
- Optimize Your B12 Status Concurrently: Nervala’s benfotiamine addresses B1 nerve protection; a separate B12 supplement (methylcobalamin form for best neural bioavailability) addresses the B12 deficiency that is extremely common in metformin users (metformin reduces B12 absorption). This combination covers the B vitamin nerve protection spectrum more completely.
- Maintain the Best Possible Glycemic Control: ALA and benfotiamine reduce the neuropathic consequences of high blood glucose — they are most effective when the blood glucose environment they are protecting against is already as controlled as possible. The supplement amplifies good glycemic management; it cannot compensate for poor glycemic control.
- Track Neuropathy Pain with a Daily NRS Score: The slow, progressive improvement in neuropathic pain is nearly invisible without objective daily tracking. Daily 0–10 NRS scores for burning pain and weekly numbness assessments reveal the progressive pattern of improvement that subjective awareness alone misses.
Frequently Asked Questions — FAQs
Q: How is Nervala different from a basic B-complex vitamin?
A: B-complex vitamins provide thiamine (standard water-soluble B1) alongside other B vitamins. Standard thiamine’s water-solubility limits its penetration into the lipid nerve environment where diabetic glucose toxicity occurs. Nervala’s benfotiamine achieves 5x the nerve tissue concentration of standard thiamine at the same oral dose. Additionally, Nervala’s 600mg ALA is a documented-efficacy clinical dose absent from B-complex vitamins entirely. The combination represents a qualitatively different intervention from basic B-vitamin supplementation.
Q: How long should I take Nervala?
A: Diabetic peripheral neuropathy’s underlying cause — the progressive nerve damage from chronic hyperglycemia — requires ongoing management. ALA and benfotiamine provide ongoing nerve protection against continued glucose toxicity and reduce ongoing oxidative nerve stress. Long-term daily supplementation is the appropriate approach for an ongoing condition, consistent with how the clinical trials demonstrating benefit were conducted.
Q: Will this work for chemotherapy-induced neuropathy?
A: ALA has been studied in chemotherapy-induced peripheral neuropathy (CIPN) with some positive findings for oxaliplatin and cisplatin neuropathy in particular. The oxidative stress mechanism ALA addresses is relevant to CIPN as well as diabetic neuropathy. Benfotiamine is less specifically studied for CIPN. Consult your oncologist before adding supplements during or after chemotherapy — potential interactions with specific chemotherapy regimens require physician evaluation.
Q: My neuropathy is in my hands, not my feet. Will this still help?
A: Yes — ALA and benfotiamine work systemically through the bloodstream, delivering nerve protection throughout the peripheral nervous system including the upper extremities. Hand and forearm neuropathy typically responds more slowly than plantar neuropathy because the distal extremity nerve fibers are more affected by the length-dependent pattern of peripheral neuropathy. Expect a longer timeline (4–6 months) for upper extremity improvements versus lower extremity.
Q: Can I take Nervala if my neuropathy is not from diabetes?
A: Yes — ALA’s antioxidant mechanisms and benfotiamine’s nerve tissue support are relevant for neuropathy regardless of cause. Idiopathic neuropathy, chemotherapy-induced neuropathy, and some inflammatory neuropathies all involve oxidative stress as a component of nerve damage. The specific glucose toxicity pathway that benfotiamine blocks is most directly relevant for diabetic neuropathy, but its general nerve protective properties extend beyond that mechanism.
Final Verdict
After 90 days, Nervala has done what years of B-complex supplementation, low-dose ALA, and pharmaceutical attempts had failed to achieve: substantially reduced the neuropathic pain that had been defining my retirement. Plantar burning from 6/10 to 2/10. Nighttime wake-ups from 4–5 to 0–1 weekly. Fingertip numbness from 6/10 to 3/10. Daily fatigue from 6.5/10 to 2.5/10. My endocrinologist validated the meaningful improvement in my symptom scores at 90 days.
As a nurse who has seen neuropathy progress and who lives with it, I wish I had known about clinical-dose ALA and benfotiamine years earlier. The difference between a 100mg basic ALA supplement and a 600mg clinical-dose formula is not incremental — it is the difference between a pharmacologically significant intervention and a gesture in the right direction.
| THE NUMBERS SPEAK CLEARLY: Plantar burning from 6/10 to 2/10. Nighttime neuropathy wake-ups near-eliminated. Fingertip numbness halved. Daily fatigue reduced by 4 points. Sleep disruption from 4–5 nights weekly to 0–1. Balance confidence improved. Endocrinologist documented meaningful symptom improvement at 90 days. For anyone with peripheral neuropathy who has tried basic B-vitamins or low-dose ALA without meaningful benefit, Nervala’s clinical-dose (600mg) ALA combined with fat-soluble benfotiamine represents a qualitatively different pharmacological approach — with a 365-day guarantee that makes the evaluation essentially risk-free. |